ArticleBiomedicines2022

Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.

Giammarco Mocci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.